MART-1 melanoma antigen-based vaccine: NCI has begun a Phase I trial

Therion Biologics Corp , Cambridge, Mass. Product: MART-1 melanoma antigen-based vaccine Indication: Metastatic melanoma Status: NCI has begun a Phase I trial in 21 to 42 patients to evaluate safety o...